Opioid Free Anesthesia and Continuous Post-operative Pulse Oximetry Monitoring in the Obese Patient

Sponsor
Université Libre de Bruxelles (Other)
Overall Status
Completed
CT.gov ID
NCT03124680
Collaborator
(none)
30
1
2
2.4
12.7

Study Details

Study Description

Brief Summary

Anaesthesia has three major components, analgesia, muscle relaxation and hypnosis.

For a long time, opioids have been covering the analgesia function. (1) When using opioids, an analgesic effect is obtained per-operatively, however, not without side-effects. Post-operative complications such as: respiratory depression, post-operative nausea and vomiting, pruritus, acute opioid tolerance and hyperalgesia, difficulty voiding and ileus, are well known.

Opioid usage is an important risk factor of postoperative desaturation. Postoperative desaturation can lead to severe hypoxemia and even tissue hypoxia, followed by obvious cardiologic and neurological complications.

Thus, in patients at risk, such as the obese patient, experts suggest reducing opioid usage.

Non-opiate protocols implemented on the obese patient have been published. Non-opiate protocols have been established using a combination of ketamine, lidocaine and an alpha-2 agonist.

The main purpose of this pilot study is to evaluate whether patients undergoing an opioid free anaesthesia regime experience less desaturation episodes during the first 24 h post-bariatric surgery than patients having received an opioid anaesthesia regime.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Opioid free
  • Combination Product: opioid group
N/A

Detailed Description

Anaesthesia has three major components, analgesia, muscle relaxation and hypnosis.

For a long time, opioids have been covering the analgesia function. When using opioids, an analgesic effect is obtained per-operatively, however, not without side-effects. Post-operative complications such as: respiratory depression, post-operative nausea and vomiting, pruritus, acute opioid tolerance and hyperalgesia, difficulty voiding and ileus, are well known. These complications may lead to a prolonged hospital stay.

Opioid usage is an important risk factor of postoperative desaturation. Postoperative desaturation can lead to severe hypoxemia and even tissue hypoxia, followed by obvious cardiologic and neurological complications.

Thus, in patients at risk, such as the obese patient, experts suggest reducing opioid usage.

Authors have indeed published non-opiate protocols implemented on the obese patient.

Non-opiate protocols have been established using a combination of ketamine, lidocaine and an alpha-2 agonist.

The main purpose of this pilot study is to evaluate whether patients undergoing an opioid free anaesthesia regime experience less desaturation episodes during the first 24 h post-bariatric surgery than patients having received an opioid anaesthesia regime.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Opioid Free Anesthesia and Continuous Post-operative Pulse Oximetry Monitoring in the Obese Patient: How About Another Approach?
Actual Study Start Date :
Apr 20, 2017
Actual Primary Completion Date :
Jul 1, 2017
Actual Study Completion Date :
Jul 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: opioid free group

Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4

Combination Product: Opioid free
Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
Other Names:
  • study group
  • Placebo Comparator: Opioid group

    Opioid group using sufentanil, lidocaine, clonidine

    Combination Product: opioid group
    Opioid anesthesia will follow the current standard approach of our hospital.
    Other Names:
  • control group
  • Outcome Measures

    Primary Outcome Measures

    1. desaturation episode evaluation [first 24 hours postoperative]

      The primary outcome of this study is to evaluate desaturation episodes during the first 24 h post-bariatric surgery in patients having received an opioid or an opioid free anaesthesia. Desaturation is defined as a decrease of oxygen desaturation equal to or exceeding 4% of the baseline value. ODI (oxygen desaturation index), the total number of desaturation events divided by the total time of monitoring in hours, will be calculated to evaluate this outcome in both groups. In case of desaturation lasting longer than 10 seconds, oxygen (via nasal canula) will be administered as per post-anaesthesia care unit protocol. SP02 will be measured for 24 hours through non-invasive monitoring.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients undergoing a gastric by-pass surgery will be screened.

    • Patients with an ASA physical status of I-II-III (BMI >30) will be included.

    • Knowledge of either French, English or Dutch will be required in order to be enrolled in this study.

    Exclusion Criteria:
    • allergy or contraindications to one of the study drugs

    • renal failure

    • hepatic failure

    • hyperthyroidism

    • AV block 2 or 3

    • severe bradycardia

    • left ventricular failure

    • unstable blood pressure

    • severe respiratory disease

    • epilepsy

    • psychiatric disturbance.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Erasme Hospital Brussels Belgium 1070

    Sponsors and Collaborators

    • Université Libre de Bruxelles

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sarah Saxena, Dr, Université Libre de Bruxelles
    ClinicalTrials.gov Identifier:
    NCT03124680
    Other Study ID Numbers:
    • OFA
    First Posted:
    Apr 24, 2017
    Last Update Posted:
    Jul 19, 2017
    Last Verified:
    Jul 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2017